Alaunos Therapeutics (TCRT) Reports Q3, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives (Streetinsider.com) - Nov 14, 2023 - P1/2 | N=180 | NCT05194735 | Sponsor: Alaunos Therapeutics | "Clinical Data from TCR-T Library Phase 1/2 Trial:...Overall, the trial showed the Company's T cells were well-tolerated in all evaluable participants with no dose-limiting toxicities (DLTs) and no immune effector cell-associated neurotoxicity syndrome (ICANS) were observed....One patient with non-small cell lung cancer (NSCLC) achieved an objective partial response with six months progression-free survival. Six other patients achieved best overall response of stable disease. The total overall response rate was 13% and disease control rate was 87% in evaluable patients with advanced, metastatic, refractory solid tumors..."
P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor
|